Epiretinal Membrane of Both EyesNCT05287009
Optical Coherence Tomography Angiography (OCTA) Changes in Patients With Epiretinal Membranes (ERM) With and Without Peeling of the Internal Limiting Membrane (ILM)
A study testing ILM nonpeeling and ILM peeling in people with Epiretinal Membrane of Both Eyes, run by Medical University of Graz at 1 site in Austria.
Trial summary
Main objective The objective is to compare two surgical options in vitrectomies for epiretinal membranes using parameters of optical coherence tomography angiography. Background State of the art treatment for epiretinal membranes consists of pars plana vitrectomy, staining of the epiretinal membrane with a blue… Read more about this study
- Who is it for?
- Ages 18 to 99 years
- Conditions the study is for
- Epiretinal Membrane of Both Eyes
- What is being tested?
- ILM nonpeeling and ILM peeling
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 51 participants
- Where
- 1 siteAustria
- Study dates
- 25 Jun 2020to 9 Mar 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 99 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patient must be able and willing to give informed consent.
- Patient must be over 18 and below 100 years of age.
- Patient must not have any significant media opacity which interferes with the examination.
- Patient must have an epiretinal membrane requiring surgery.
Who cannot join
- Unwilling or unable to provide informed consent
- Under 18 or over 100 years of age
- Significant media opacities
- Systemic pathologies making an examination difficult or cumbersome to the patient
- Secondary epiretinal membranes
- Bilateral epiretinal membranes
Show all 17Show fewer
- Macular holes
- Lamellar holes
- Pseudo holes
- Glaucoma
- Diabetes
- Anisometropia > 2 diopters
- High myopia (spherical equivalent > 6 diopters and/or axial length > 26 mm
- Other retinal or ophthalmic pathologies except moderate cataract
- OCTA scan signal strength < 50
- Low image quality
- Failure of automatic layer segmentation
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Optical Coherence Tomography Angiography (AngioVueTM, Optovue Inc., Fremont, Calif., USA) Changes in Patients With Epiretinal Membranes (ERM) With and Without Peeling of the Internal Limiting Membrane (ILM) - a Pilot Study
Main objective
The objective is to compare two surgical options in vitrectomies for epiretinal membranes using parameters of optical coherence tomography angiography.
Read more
Background
State of the art treatment for epiretinal membranes consists of pars plana vitrectomy, staining of the epiretinal membrane with a blue colouring dye and epiretinal membrane peeling. The vitrectomized space is filled with fluid (balanced salt solution) during the procedure and the fluid can optionally be replaced with air as a final step. After ERM peeling (but before the selection of the tamponade), the internal limiting membrane (the innermost layer of the retina) is either peeled as well or left untouched and the question which method should be preferred has been a hot topic in recent years. The investigators want to investigate possible effects of the used method (peeling vs. nonpeeling) on retinal perfusion parameters represented by OCTA. Two epiretinal membrane patient groups will therefore be formed: The first group's (group 1) ILM will be peeled, the second group's (group 2) ILM will not be peeled. After recruitement, patients will therefore be electronically randomized to one of the two groups. The groups will then be compared by the means of OCTA.
Study design
- Since there are no previous data on our research question, this investigation is defined as a pilot study.
- 40 patients with epiretinal membranes will be included. This appears to be a reasonable number given the incidence of epiretinal membranes. Previous studies that compared peeling versus nonpeeling in ERM used similar sample sizes. The detectable effect size was calculated at d = 0.91. We intend to complete this pilot study within 9 months.
- Randomization will be performed using electronic randomization. 20 patients each will be randomized to either group 1 or group 2.
- Both eyes in each patient will be imaged.
- No treatment decisions will be made based on OCTA findings. Treatment decisions will be made according to the clinic's standard of care.
- Three follow-up visits specific to the study are needed. These visits will be scheduled one week, one month and three months after surgery. All other preoperative and follow-up visits will be decided by the treating physician and follow the clinic standard of care.
Examinations
- Distance visual acuity using ETDRS (Early Treatment Diabetic Retinopathy Study) standard at 4 meters as per clinic standard of care.
- Tonometry as per clinic standard of care.
- Slit-lamp evaluation as per clinic standard of care.
- Arterial blood pressure.
- Axial eye length.
- Heidelberg Spectralis conventional OCT.
- The following 2 AngioVue scans will be taken:
- One 3mm x 3mm, 304 x 304 A-scan OCTA of the macula B. One 6mm x 6mm, 304 x 304 A-scan OCTA of the macula
Hypothesis
The null hypothesis of our investigation indicates that there are no statistically significant differences in OCTA perfusion parameters based on the used option.
The alternative hypothesis states that there are statistically significant differences in OCTA perfusion parameters based on the used option.
Primary Objective
To demonstrate possible differences in OCTA perfusion parameters based on the used option.
Secondary Objectives
To assess the feasibility of the AngioVue optical coherence tomography angiography system in evaluating subtle changes in the retinal perfusion of patients with epiretinal membranes.
- Conditions
- Epiretinal Membrane of Both Eyes
- Being tested
- ILM nonpeeling, ILM peeling
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ILM nonpeelingProcedure or surgery
ILM is not peeled after ERM removal
ILM peelingProcedure or surgery
ILM is peeled after ERM removal
| Study group | Role | What they receive |
|---|---|---|
| ILM nonpeeling | Experimental | Not described Receives: Procedure: ILM nonpeeling |
| ILM peeling | Other | Not described Receives: Procedure: ILM peeling |
What is being measured
The primary outcome is the main question the study is designed to answer.
Superficial capillary plexus foveal avascular zone area
Superficial capillary plexus foveal avascular zone area (SCP FAZ) change (preoperative to postoperative). The SCP FAZ represents the area of the macula where blood vessels are not seen in OCTA under physiologic conditions. It has previously been reported that the FAZ narrows during ERM development and enlarges after ERM removal.
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Mar 2022
- Study start25 Jun 2020
- Primary completion9 Mar 2022
- Study completion9 Mar 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Epiretinal Membrane of Both EyesStudies of the same condition, open and under way.
- More trials run by Medical University of GrazThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 51 participants (actual)
Sponsor and investigators
- Lead sponsor
- Medical University of Graz
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05287009
- Sponsor's protocol ID
- 32-443 ex 19/20
- Status last verified
- Mar 2022
- First submitted
- 10 Mar 2022
- Last updated
- 31 Mar 2022
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Gabriel M, Djavid D, Innauer F, Ivastinovic D, Seidel G, Mayer-Xanthaki C, Ansari-Shahrezaei S, Wedrich A, Haas A. CHANGES OF OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY PARAMETERS AFTER INTERNAL LIMITING MEMBRANE PEELING COMPARED WITH NONPEELING IN EPIRETINAL MEMBRANE SURGERY. Retina. 2022 Oct 1;42(10):1867-1873. doi: 10.1097/IAE.0000000000003567.
PubMed 35976252
Study at a glance
From the registry record, last updated by the sponsor on 31 Mar 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Optical Coherence Tomography Angiography (AngioVueTM, Optovue Inc., Fremont, Calif., USA) Changes in Patients With Epiretinal Membranes (ERM) With and Without Peeling of the Internal Limiting Membrane (ILM) - a Pilot Study
- ClinicalTrials.gov ID
- NCT05287009
- Acronym / sponsor ID
- 32-443 ex 19/20
- Conditions
- Epiretinal Membrane of Both Eyes
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 51 participants (actual)
- Lead sponsor
- Medical University of GrazUniversity, hospital or other
- Study start
- 25 Jun 2020 (actual)
- Primary completion
- 9 Mar 2022 (actual)
- Study completion
- 9 Mar 2022 (actual)
- First posted
- 18 Mar 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Main objective
The objective is to compare two surgical options in vitrectomies for epiretinal membranes using parameters of optical coherence tomography angiography.
Background
State of the art treatment for epiretinal membranes consists of pars plana vitrectomy, staining of the epiretinal membrane with a blue colouring dye and epiretinal membrane peeling. The vitrectomized space is filled with fluid (balanced salt solution) during the procedure and the fluid can optionally be replaced with air as a final step. After ERM peeling (but before the selection of the tamponade), the internal limiting membrane (the innermost layer of the retina) is either peeled as well or left untouched and the question which method should be preferred has been a hot topic in recent years. The investigators want to investigate possible effects of the used method (peeling vs. nonpeeling) on retinal perfusion parameters represented by OCTA. Two epiretinal membrane patient groups will therefore be formed: The first group's (group 1) ILM will be peeled, the second group's (group 2) ILM will not be peeled. After recruitement, patients will therefore be electronically randomized to one of the two groups. The groups will then be compared by the means of OCTA.
Study design
- Since there are no previous data on our research question, this investigation is defined as a pilot study.
- 40 patients with epiretinal membranes will be included. This appears to be a reasonable number given the incidence of epiretinal membranes. Previous studies that compared peeling versus nonpeeling in ERM used similar sample sizes. The detectable effect size was calculated at d = 0.91. We intend to complete this pilot study within 9 months.
- Randomization will be performed using electronic randomization. 20 patients each will be randomized to either group 1 or group 2.
- Both eyes in each patient will be imaged.
- No treatment decisions will be made based on OCTA findings. Treatment decisions will be made according to the clinic's standard of care.
- Three follow-up visits specific to the study are needed. These visits will be scheduled one week, one month and three months after surgery. All other preoperative and follow-up visits will be decided by the treating physician and follow the clinic standard of care.
Examinations
- Distance visual acuity using ETDRS (Early Treatment Diabetic Retinopathy Study) standard at 4 meters as per clinic standard of care.
- Tonometry as per clinic standard of care.
- Slit-lamp evaluation as per clinic standard of care.
- Arterial blood pressure.
- Axial eye length.
- Heidelberg Spectralis conventional OCT.
- The following 2 AngioVue scans will be taken:
- One 3mm x 3mm, 304 x 304 A-scan OCTA of the macula B. One 6mm x 6mm, 304 x 304 A-scan OCTA of the macula
Hypothesis
The null hypothesis of our investigation indicates that there are no statistically significant differences in OCTA perfusion parameters based on the used option.
The alternative hypothesis states that there are statistically significant differences in OCTA perfusion parameters based on the used option.
Primary Objective
To demonstrate possible differences in OCTA perfusion parameters based on the used option.
Secondary Objectives
To assess the feasibility of the AngioVue optical coherence tomography angiography system in evaluating subtle changes in the retinal perfusion of patients with epiretinal membranes.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| ILM nonpeeling | Experimental | Procedure: ILM nonpeeling |
| ILM peeling | Other | Procedure: ILM peeling |
Who may qualify
- Ages
- 18 to 99 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Patient must be able and willing to give informed consent.
- Patient must be over 18 and below 100 years of age.
- Patient must not have any significant media opacity which interferes with the examination.
- Patient must have an epiretinal membrane requiring surgery.
Key exclusion criteria (17 listed)
- Unwilling or unable to provide informed consent
- Under 18 or over 100 years of age
- Significant media opacities
- Systemic pathologies making an examination difficult or cumbersome to the patient
- Secondary epiretinal membranes
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ILM nonpeelingILM is not peeled after ERM removal | Procedure or surgery | ILM nonpeeling |
| ILM peelingILM is peeled after ERM removal | Procedure or surgery | ILM peeling |
Primary outcome
Superficial capillary plexus foveal avascular zone area
Time frame: 3 months
Superficial capillary plexus foveal avascular zone area (SCP FAZ) change (preoperative to postoperative). The SCP FAZ represents the area of the macula where blood vessels are not seen in OCTA under physiologic conditions. It has previously been reported that the FAZ narrows during ERM development and enlarges after ERM removal.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Mar 2022.
- Derived from this study: PubMed 35976252Gabriel M, Djavid D, Innauer F, Ivastinovic D, Seidel G, Mayer-Xanthaki C, Ansari-Shahrezaei S, Wedrich A, Haas A. CHANGES OF OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY PARAMETERS AFTER INTERNAL LIMITING MEMBRANE PEELING COMPARED WITH NONPEELING IN EPIRETINAL MEMBRANE SURGERY. Retina. 2022 Oct 1;42(10):1867-1873. doi: 10.1097/IAE.0000000000003567.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing ILM nonpeeling and ILM peeling in people with Epiretinal Membrane of Both Eyes, run by Medical University of Graz at 1 site in Austria.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 31 Mar 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Austria. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Superficial capillary plexus foveal avascular zone area (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05287009, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Mar 2022.